Loading stock…

Eastman Chemical Company (EMN) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Eastman Chemical Company

EMNMarket cap $7.23BPrice $63.3

Country🇺🇸United States

SectorMaterials

IndustryChemicals

Produces specialty chemicals and materials — plastics, fibers, and coatings — used in everything from phone screens to car interiors. Its molecular recycling technology breaks down plastic waste that traditional recycling can't touch, turning trash back into virgin-quality material.

In Bastion Portfolios?

52W Return+6%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-6%1

Revenue Forecast

Rev CAGR (1y)+6%4

Rev CAGR (3y)+4%3

Rev CAGR (5y)+1%2

Earnings Forecast

EPS Growth Y+1+57%9

EPS Growth Y+2+7%6

EPS Growth Y+3+9%6

Quality

Margins

EBIT Margin10%4

Net Income Margin5%4

Free Cash Flow Margin6%4

Debt

Net Debt/EBITDA3.23

Efficiency

ROE7%4

ROA3%5

Earnings Stability77

GEAR+WEAK29

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)99

P/E Ratio (Forward 3y)89

P/BV1.29

EV Multiples

EV/EBITDA Fwd88

EV/EBIT Fwd118

Yield

Free Cash Flow Yield7.5%8

Dividend Yield5.3%9

Momentum

Short term

1 month return-9%3

3 month return-4%5

YTD return+3%5

Mid term

Price vs 52wHigh79%5

1 year return+7%6

Long term

3 year return-3%3

5 year return-27%2

Risk Shield

Price Risk

Beta1.04

Volatility32%6

Free Cash Flow

Free Cash Flow Margin6%4

Free Cash Flow Yield7.5%8

Quality

ROCE7%4

Earnings Stability77

Net Debt/EBITDA3.23

02Growth

Is it actually growing, and how fast?

EMNEastman Chemical

Revenue FY25$8.8B

GROWTH RATING↗

WEAK20 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-6%1

Revenue, next 1Y+6%4

Revenue, next 3Y, CAGR+4%3

Revenue, next 5Y, CAGR+1%2

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+57%9

EPS growth, FY27E+7%6

EPS growth, FY28E+9%6

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow faster than sales (EPS about 9%/yr vs revenue 4%/yr), so margins should widen.

WATCH

After shrinking over the last 3 years, revenue is set to grow 4%/yr from here.

WEAKNESSES

Growth is the weak spot here, trailing 80% of companies worldwide.

Revenue fell 6%/yr over the last 3 years, behind 90% of companies worldwide.1/10

Revenue is set to grow 4%/yr over the next 3 years, behind most of the market.3/10

Over five years revenue is set to grow 1%/yr, behind 80% of companies worldwide.2/10

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK25 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-9%3

3-month return-4%5

YTD return+3%5

MID & LONG-TERM▾SCORE

% of 52-week high79%5

1-year return+7%6

3-year return-3%3

5-year return-27%2

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

It's up 7% over the past year, but 21% below its 52-week high. That is a touch ahead of the market.

Returns sit at the market level over three months (-4%) and so far this year (+3%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-3.2% over three years and -27% over five), behind 70% of the market.

The stock is underperforming over the past month (-9%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Eastman Chemical Company. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

EMNEastman Chemical

Revenue FY25$8.8B

GROWTH RATING↗

WEAK20 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-6%1

Revenue, next 1Y+6%4

Revenue, next 3Y, CAGR+4%3

Revenue, next 5Y, CAGR+1%2

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+57%9

EPS growth, FY27E+7%6

EPS growth, FY28E+9%6

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow faster than sales (EPS about 9%/yr vs revenue 4%/yr), so margins should widen.

WATCH

After shrinking over the last 3 years, revenue is set to grow 4%/yr from here.

WEAKNESSES

Growth is the weak spot here, trailing 80% of companies worldwide.

Revenue fell 6%/yr over the last 3 years, behind 90% of companies worldwide.1/10

Revenue is set to grow 4%/yr over the next 3 years, behind most of the market.3/10

Over five years revenue is set to grow 1%/yr, behind 80% of companies worldwide.2/10

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK25 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-9%3

3-month return-4%5

YTD return+3%5

MID & LONG-TERM▾SCORE

% of 52-week high79%5

1-year return+7%6

3-year return-3%3

5-year return-27%2

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

It's up 7% over the past year, but 21% below its 52-week high. That is a touch ahead of the market.

Returns sit at the market level over three months (-4%) and so far this year (+3%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-3.2% over three years and -27% over five), behind 70% of the market.

The stock is underperforming over the past month (-9%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Eastman Chemical Company. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community